Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Tumor-Informed Circulating Tumor DNA Monitoring for Predicting Outcomes in Patients With Head and Neck Squamous Cell Carcinoma

This real-world series tested a personalized tumor-informed assay (Signatera) in 97 patients with stage I-IV HNSCC (500 plasma samples). MRD positivity in the early window after definitive local treatment was associated with shorter progression-free survival (HR 6.39) and overall survival (HR 25.72). Positivity during later surveillance was associated with shorter progression-free survival (HR 38.87) and preceded radiographic progression by a median of 4.3 months, regardless of p16 status.

Advances in Radiation OncologyPubMed 42999361DOI 10.1016/j.adro.2026.102205